NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset
New York, Jan 14, 2026, 08:52 EST — Premarket NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide…
